ADC Therapeutics SA (ADCT) — Cash Flow-to-Debt Ratio
ADC Therapeutics SA (ADCT) has a Cash Flow-to-Debt Ratio of -0.06x as of March 2026, meaning its operating cash flow of $-29.71 Million could theoretically repay 0% of its total liabilities ($507.87 Million) in one year. See ADCT cash flow after capex ratio to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
ADC Therapeutics SA Cash Flow-to-Debt Ratio (2017–2025)
Historical debt coverage capacity for ADC Therapeutics SA across 9 annual periods. Also explore ADCT net asset momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for ADC Therapeutics SA (2017–2025)
Year-by-year debt coverage analysis for ADC Therapeutics SA. For market capitalisation and broader financial context, see ADC Therapeutics SA stock valuation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.28x | $-141.17 Million | $508.98 Million | ▼ -17.5% |
| 2024 | -0.24x | $-123.83 Million | $524.62 Million | ▼ 0.0% |
| 2023 | -0.24x | $-118.69 Million | $503.03 Million | ▲ +29.8% |
| 2022 | -0.34x | $-138.31 Million | $411.41 Million | ▲ +34.9% |
| 2021 | -0.52x | $-233.38 Million | $451.88 Million | ▲ +45.5% |
| 2020 | -0.95x | $-168.73 Million | $178.19 Million | ▲ +79.3% |
| 2019 | -4.58x | $-121.58 Million | $26.53 Million | ▲ +8.2% |
| 2018 | -4.99x | $-121.36 Million | $24.32 Million | ▼ -51.7% |
| 2017 | -3.29x | $-74.94 Million | $22.78 Million | — |